A Phase 3 interventional study of MED3000 (Male) and Tadalafil 5mg (Male) in Erectile Dysfunction, sponsored by Futura Medical Developments Ltd.. Completed at 18 sites in 4 countries. Open to male participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by Futura Medical Developments Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 37th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2021, is one of 19 in phase 3, and was the 39th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 22 Years to 70 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Futura Medical Developments Ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Futura Medical Developments Ltd. has 4 studies filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks. Eligible patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MED3000 gel formulation topically applied to the glans penis
Device: MED3000 (Male) · Device: MED3000 (Female)
Tadalafil (5 mg) tablets to be taken orally
Drug: Tadalafil 5mg (Male) · Drug: Tadalafil 5mg (Female)
Gel formulation
Tablets
Gel formulation
Tablets
Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at Week 24
Co-primary objectives: * Demonstrate an improvement compared to baseline of erectile function, in patients randomised to receive MED3000, using the IIEF-EF patient reported outcome instrument. * Observe a mean change from baseline of the IIEF-EF, in patients randomised to MED3000, greater or equal to the minimal clinically importance difference of 4. The IIEF is a validated questionnaire, consisting of 15 questions, for detecting treatment changes in EF. The EF domain of IIEF is derived using questions 1, 2, 3, 4, 5 and 15. A score of 0 to 5 is awarded to each of questions 1 to 5 and a score of 1 to 5 is awarded to question 15. Higher scores indicate better sexual function. Domain score is computed by summing the scores for individual questions. The minimum and maximum possible scores are 1 and 30 respectively. Patients with a score of 21 or less are considered to have ED. Change from baseline = Week 24 score - Baseline score.
Time frame: Baseline and Week 24
Percentage of Uses Per Patient That Led to an Onset of Erection Within a Certain Period of Time in Patients Randomised to MED3000.
Demonstrate a speed of onset of action from application of MED3000 gel to the time when patient notices their erection starting. Percentage of MED3000 uses per patient that resulted in the patient noticing their erection starting within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 1 indicated a time of 5 (10, 15) minutes or less. Question 1 of the Onset of Action questionnaire: - After application of the gel/taking medication, when did you begin to notice your erection starting?
Time frame: 24 weeks
Percentage of Uses Per Patient That Led to an Onset of Action Within a Certain Period of Time in Patients Randomised to MED3000.
Demonstrate a speed of onset of action from application of MED3000 gel to the time when the patients is able to have penetrative sex. Percentage of MED3000 uses per patient that resulted in the patient being able to have penetrative sex within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 2 indicated a time of 5 (10, 15) minutes or less. Question 2 of the Onset of Action questionnaire: - After application of the gel/taking medication, when were you able to have penetrative sex?
Time frame: 24 weeks
The first informed consent was on September 14, 2021 and the last study visit was on June 13, 2022.
| Milestone | MED3000 | Tadalafil |
|---|---|---|
| Started | 96 | 96 |
| Received treatment | 94 | 94 |
| Completed | 82 | 92 |
| Not completed | 14 | 4 |
| Withdrew: Withdrawal by subject | 8 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Both patients moved to another country | 4 | 0 |
Co-primary objectives: * Demonstrate an improvement compared to baseline of erectile function, in patients randomised to receive MED3000, using the IIEF-EF patient reported outcome instrument. * Observe a mean change from baseline of the IIEF-EF, in patients randomised to MED3000, greater or equal to the minimal clinically importance difference of 4. The IIEF is a validated questionnaire, consisting of 15 questions, for detecting treatment changes in EF. The EF domain of IIEF is derived using questions 1, 2, 3, 4, 5 and 15. A score of 0 to 5 is awarded to each of questions 1 to 5 and a score of 1 to 5 is awarded to question 15. Higher scores indicate better sexual function. Domain score is computed by summing the scores for individual questions. The minimum and maximum possible scores are 1 and 30 respectively. Patients with a score of 21 or less are considered to have ED. Change from baseline = Week 24 score - Baseline score.
| Score on a scale | MED3000 |
|---|---|
| Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at Week 24 | 5.73 ± 1.00 |
Demonstrate a speed of onset of action from application of MED3000 gel to the time when patient notices their erection starting. Percentage of MED3000 uses per patient that resulted in the patient noticing their erection starting within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 1 indicated a time of 5 (10, 15) minutes or less. Question 1 of the Onset of Action questionnaire: - After application of the gel/taking medication, when did you begin to notice your erection starting?
| percentage of uses per patient | MED3000 |
|---|---|
| 15 minutes | 62.59 ± 39.18 |
| 10 minutes | 47.81 ± 36.26 |
| 5 minutes | 24.01 ± 33.43 |
Demonstrate a speed of onset of action from application of MED3000 gel to the time when the patients is able to have penetrative sex. Percentage of MED3000 uses per patient that resulted in the patient being able to have penetrative sex within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 2 indicated a time of 5 (10, 15) minutes or less. Question 2 of the Onset of Action questionnaire: - After application of the gel/taking medication, when were you able to have penetrative sex?
| percentage of uses per patient | MED3000 |
|---|---|
| 15 minutes | 55.70 ± 36.13 |
| 10 minutes | 31.91 ± 29.30 |
| 5 minutes | 13.72 ± 22.33 |
Collected over 29 Weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MED3000 | 0/94 (0%) | 0/94 (0%) | 10/47 (21.3%) |
| Tadalafil | 0/94 (0%) | 1/94 (1.1%) | 16/47 (34%) |
| Event | MED3000 | Tadalafil |
|---|---|---|
| AppendicitisInfections and infestations | 0/94 | 1/94 |
| Event | MED3000 | Tadalafil |
|---|---|---|
| Headache (Male)Nervous system disorders | 2/47 | 9/47 |
| Headache (Female)Nervous system disorders | 3/47 | 0/47 |
| Nausea (Male)Gastrointestinal disorders | 2/47 | 0/47 |
| Non-cardiac chest pain (Male)General disorders | 0/47 | 2/47 |
| Back Pain (Male)Musculoskeletal and connective tissue disorders | 0/47 | 2/47 |
| Abdominal distension (Male)Gastrointestinal disorders | 1/47 | 1/47 |
| Gamma-glutamyltransferase increased (Male)Investigations | 1/47 | 1/47 |
| Pain in extremity (Male)Musculoskeletal and connective tissue disorders | 1/47 | 1/47 |
Regional enrolment details are combined for both the male participants and their female partners.
| Age, Continuous(Years) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Male | 46.1 ± 13.5 | 41.5 ± 11.5 | 43.8 ± 12.7 |
| Female | 43.3 ± 13.9 | 40.0 ± 11.5 | 41.6 ± 12.8 |
| Age, Continuous(Years) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Male | 44.5 (22 to 68) | 39.0 (23 to 68) | 40.5 (22 to 68) |
| Female | 39.5 (20 to 69) | 38.0 (19 to 65) | 39.0 (19 to 69) |
| Age, Customized(Participants) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Male — 22-29 | 5 | 7 | 12 |
| Male — 30-39 | 16 | 18 | 34 |
| Male — 40-49 | 5 | 13 | 18 |
| Male — 50-59 | 10 | 5 | 15 |
| Male — 60-70 | 12 | 5 | 17 |
| Male — <22 | 0 | 0 | 0 |
| Female — 22-29 | 10 | 8 | 18 |
| Female — 30-39 | 13 | 18 | 31 |
| Female — 40-49 | 3 | 11 | 14 |
| Female — 50-59 | 16 | 7 | 23 |
| Female — 60-70 | 5 | 3 | 8 |
| Female — <22 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Female | 48 | 48 | 96 |
| Male | 48 | 48 | 96 |
| Ethnicity (NIH/OMB)(Participants) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Male — Hispanic or Latino | 0 | 0 | 0 |
| Male — Not Hispanic or Latino | 48 | 48 | 96 |
| Male — Unknown or Not Reported | 0 | 0 | 0 |
| Female — Hispanic or Latino | 0 | 0 | 0 |
| Female — Not Hispanic or Latino | 48 | 48 | 96 |
| Female — Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| United States | 8 | 10 | 18 |
| Poland | 52 | 56 | 108 |
| Georgia | 32 | 28 | 60 |
| Bulgaria | 4 | 2 | 6 |
| Height(cm) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Mean | 179.20 ± 7.24 | 179.43 ± 7.66 | 179.31 ± 7.41 |
| Height(cm) | MED3000 | Tadalafil | Total |
|---|---|---|---|
| Median | 177.50 (167.0 to 196.0) | 180.00 (156.0 to 194.0) | 179.00 (156.0 to 196.0) |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Jul 2022, 9 months.
Results were first posted in Sep 2023, 1 year 2 months after primary completion.
Of 16 phase 3 interventional studies under Erectile Dysfunction, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil
Futura Medical Developments Ltd.